EUCTR2013-000056-18-DE进行中（未招募）不适用
Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to hay fever patients. A Phase IIa dose-escalation study.
BioTech Tools S.A.0 个研究点开始时间: 2013年2月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed and dated Informed Consent Form by a legally competent patient
- •Female or male patients aged 18–70 years
- •The patients are in good physical and mental health according to his/her medical history and vital signs
- •Non-pregnant, non-lactating females with adequate contraception (see Annex XX.3)
- •Females unable to bear children must have signed the form for adequate contraceptive protection (see Annex XX.3) (i.e. tubule ligation, hysterectomy, or post-menopausal (defined as a minimum of one year since the last menstrual period))
- •Allergy diagnosis:
- •oA medical history of moderate to severe seasonal allergic rhinoconjunctivitis (SAR) for the grass pollen season during at least the two previous years
- •oA positive skin prick test (wheal diameter = 3 mm) to grass-pollen mixture, histamine wheal = 3 mm, NaCl control reaction = 2 mm
- •oSpecific IgE against grass pollen (IgE > 0.7 kU/l)
- •oPatients treated with anti-allergic medication for at least 2 years prior to enrolment
- •In asthmatic patients:
- •oConfirmed diagnosis of controlled asthma according to GINA-guidelines (GINA 2006)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •Simultaneous participation in other clinical trials or previous participation within 30 days before inclusion
- •Previous immunotherapy with grass allergens within the last 5 years,
- •Ongoing immunotherapy
- •Patients being in any relationship or dependence with the Sponsor and/ or Investigator
- •Inability to understand instructions/ study documents
- •Patients with a history of hypersensitivity to the excipients of investigational products
- •Patients with partly controlled or uncontrolled asthma
- •Chronic asthma or emphysema, particularly with a FEV 1 <80% of the predicted value (ECSC)
- •Patients symptomatic to perennial inhalant allergens to which the subjects are regularly exposed.
- •Patients with a history of renal disease or chronic hepatic disease
- •Patients with malignant disease,
- •Patients with a know severe autoimmune disease and patients with a positive test to ANA, ANCA or ASCA
- •Patients with any chronic disease which may impair the patient’s ability to participate in the trial (i.e. severe congestive heart failure, active gastric ulcer, inflammatory bowel disease, uncontrolled diabetes mellitus, etc…)
- •Patients requiring beta-blockers/ACE-inhibitors medication
- •Patients with any contraindication for the use of adrenaline
- •Patients with febrile illness (> 37.5°C, oral)
- •Patients with a known positive serology for HIV-1/2, HBV or HCV
- •Patients who are immunocompromised by medication or illness, have received a vaccine, corticoids or immunosuppressive medications within 1 month before trial entry
- •Female patients who are pregnant, lactating, or of child-bearing potential and not protected from pregnancy by a sufficiently reliable method (see Annex XX.3)
- •Consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 3 weeks preceding the trial (screening visit)
- •Patients with laboratory values greater than grade 1 according to the FDA Guidance for Industry for preventive Vaccine Trials (FDA 2007)
- •Unreliable patients including non-compliant patients, patients with known alcoholism or drug abuse or with a history of a serious psychiatric disorder as well as patients unwilling to give informed consent or to abide by the requirements of the protocol
研究者
相似试验
进行中（未招募）
1 期
Clinical study with a new medication (grass pollen - ASIT+TM or gpASIT+TM) administered subcutaneously with or without the new immunoregulating agent (DnaK) for the treatment of hay fever.EUCTR2011-004486-33-BEBioTech Tools S.A.
已完成
4 期
Protection and Safety of rabies vaccine when administered intradermallyCTRI/2012/06/002720I70
进行中（未招募）
1 期
Clinical efficacy, immunogenicity, clinical tolerability and assessment of safety of gpASIT+TM administered orally, according to two administration schedules, for the prophylaxis of seasonal grass pollen rhinoconjunctivitis - Not availableTreatment of seasonal grass pollen rhinoconjunctivitisMedDRA version: 12.1Level: LLTClassification code 10019170Term: Hay feverEUCTR2010-023176-12-BEBiotech Tools sa414
Unknown
3 期
A clinical trial to study immunogenicity and safety of Purified Chick Embryo Cell Culture Rabies Vaccine administered intradermallyCTRI/2010/091/000509Cadila Healthcare Ltd36
已完成
3 期
Safety and immunogenicity of rabies vaccines in animal bite cases administered using new one week intradermal regimeCTRI/2012/12/003230Department of Community Medicine Kempegowda Institute of Medical Sciences KIMS80